Telix Presented P-III Results from TLX250-CDx for Kidney Cancer Imaging Study at the ASCO GU 2023
Shots:
- The trial results achieved 1EPs and 2EPs and showed an overall sensitivity of (86%), specificity (87%), PPV (93%), NPV (75%), accuracy (86%) for detection of ccRCC in tumors ≤4cm ("T1a" classification) along with safety and tolerability also no unexpected safety signals were observed
- A case study demonstrated the ability to identify and detect the clear cell phenotype and provide a non-invasive method of diagnosing the presence and spread of ccRCC even in ≤2cm renal masses
- In the P-III study (ZIRCON) patients (n=300) were dosed TLX250-CDx, of which 284 evaluable patients received TLX250-CDx as monotx. while a tumor sample from surgical resection was used as the standard of truth comparator
Ref: PRNewswire | Image: Telix Pharmaceuticals
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
